Pharma 2017-03 regular tender 01 Tender in Australia - 14874966

Procurement Summary

Country: Australia

Summary: Pharma 2017-03 regular tender 01

Deadline: 11 Aug 2017

Posting Date: 19 Jul 2017

Other Information

Notice Type: Tender

TOT Ref.No.: 14874966

Document Ref. No.: Pharma201703

Competition: ICB

Financier: Self Financed

Purchaser Ownership: -

Tender Value: Refer Document

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

The department of health (doh) is requesting offers of pricing for molecules within the pharmaceuticals therapeutic groups below:
drugs-alimentary tract & metabolism

drugs-antineoplastic&immunomodulating ag

drugs-antiparasitic, insecticide, repell

drugs-blood & blood forming organs

drugs-cardiovascular system

drugs-dermatologicals

drugs-general antiinfective-systemic use

drugs-genitourinary system & sex hormone

drugs-muscolo skeletal

drugs-nervous system

drugs-respiratory system

drugs-sensory organs

drugs-systemic hormonal prep ex sex hormone

drugs-various

depending on requirements these pharmaceuticals specifically include:
bivalirudin

bleomycin

bosentan

busulfan

chlorhexidine

cisatracurium

citalopram

desvenlafaxine

dexamethasone

duloxetine

eformoterol

emtricitabine-tenofovir

enoxaparin

ephedrine

escitalopram

fentanyl

fluorescein

fluoxetine

fluticasone

fluvoxamine

irinotecan

japanese encephalitis

levetiracetam

linzeolid

macrogol

meropenem

moxifloxacin

naloxone

nebivolol

octreotide

palonosetron

paroxetine

pregabalin

remifentanil

sertraline

sevoflurane

sodium bicarbonate

sugammadex

tobramycin

tranexamic acid

valganciclovir

venlafaxine

for detailed information on the specific pharmaceuticals goods being sought under this tender, please review the "rfo therapeutic group pharma 2017-03" spreadsheet in the specification secion in this q tender.
In order to submit an offer, offerors must complete the worksheet titled

rfo therapeutic group pharma 2017-03
offerors may submit pricing for all or part of the requirements detailed within the workbooks.

Offerors must ensure pricing is calculated as per the pack size and uom`s described in the rfo therapeutic group pharma 2017-03 worksheet

offerors must ensure that information submitted for offer must be complete, accurate and complies with the rfo therapeutic group pharma 2017-03 worksheet

when responding, offerors must provide information relevant to therapeutic goods administration (tga) registered indications and pbs listings

other documentation (brochures etc.) to support the offer can be submitted with the offer.

Offers are to be submitted electronically, via q-tenders - no tender submission will be accepted outside the q-tenders system

the format and or structure of the rfo therapeutic group pharma 2017-03 worksheet is not to be change, deviations from the worksheets format and structure could result in the submission evaluation being inadmissible

only rows may be added to the rfo therapeutic group pharma 2017-03 worksheet to accommodate additional product presentations, strengths or pack size variants. The format must be consistent

artwork/packaging to be submitted with the offer.

Request for offer timeline

clarification close date: all clarifications are required to be submitted via

Documents

 Tender Notice